We’re pleased to share that Ovid Therapeutics has entered a definitive agreement with Immedica Pharma AB for the sale of our future ganaxolone royalty rights outside China. The deal provides non-dilutive capital to support our core pipeline. Read more:

Ovid CEO Jeremy Levin will moderate “Supporting Research at the Intersection of Policy and Science” at #MITCEO later today. He’ll lead a timely discussion with Congressman Jake Auchincloss, former FDA Commissioner Dr. Robert Califf, and MIT President Emerita Dr. Susan Hockfield.

Thank you to everyone who joined us for Biomarkers in Epilepsy. Biomarkers are changing how we approach anti-seizure drug development - offering earlier insights and helping reduce risk. Dr. Alex Rotenberg joined us to share how this applies to OV329. Watch the replay:

We’re proud to celebrate Meg Alexander, Ovid’s President & COO, as one of @InVivo_Citeline’s 2025 Rising Leaders. She reflects on bold decisions, team-driven leadership, and the future of innovation in neurology. Read the interview:

Join Ovid leadership and Dr. Alexander Rotenberg at 9:30 AM ET today for a conversation on how biomarkers are shaping the future of epilepsy research and anti-seizure drug development - featuring OV329, our next-gen GABA-AT inhibitor. Watch here:

Ovid Therapeutics will host Biomarkers in Epilepsy, an investor and media event, on June 12 from 9:30–10:30 AM ET. The event will highlight the role of biomarkers in epilepsy research, with a focus on OV329 and insights from Dr. Alexander Rotenberg. Register here:

Today, we announced our Q1 2025 results and business updates. In a pivotal year, we are focused on key milestones, including data readouts for OV329 and OV350, and advancing small molecule therapies to restore neural balance in serious neurological conditions. Learn more:

We’re excited to announce that Ovid President & COO, Meg Alexander will be presenting at the 24th Annual Needham Virtual Healthcare Conference on April 7th. Read the full announcement, including details for accessing the webcast, here:

Today, we shared our Q4 2024 results, highlighting key business developments and a major milestone with OV350, now in a first-in-human study—furthering our commitment to addressing the neurological symptoms that matter most to patients. Learn more:

Pleased to welcome Dr. Stelios Papadopoulos to our Board of Directors! His leadership & strategic insights will be invaluable as Ovid continues its mission to develop transformative medicines for brain conditions with significant unmet need. Learn more:

Our President and COO Meg Alexander will be presenting at the TD Cowen 45th Annual Health Care Conference. Read the full announcement, including details for accessing the webcast:

Small molecules have the potential to make a big impact on CNS. As @jmaxlevin explains, they target specific receptors, offering potentially effective therapies with fewer side effects. At Ovid, we’re advancing assets like OV350, which activate KCC2 to restore brain balance.

Ovid’s President and COO, Meg Alexander, was recently featured in the final part of @PharmaScrip's “Scrip Asks… What Does 2025 Hold For Biopharma?” . Read Meg’s full quote on the advancements in neurotherapeutics in the article by @ScripEleanor here:

By targeting hyperexcitability, directly activating KCC2 could unlock new therapeutic possibilities. Listen to Dr. Noebels explain why this precision approach is key. ​. #KCC2

Congrats to Dr. Richard Silverman and team on their study of OV329 in @PNASNews ! This investigational GABA-AT inhibitor shows promise at dampening neuronal excitability and offering therapeutic benefit beyond epilepsy. Learn more: